Abstract 1926: Elevated Serum Levels of Platelet Reactivity Enhancing Oxidized Choline Glycerophospholipids in Patients with Acute Coronary Syndromes and Reduction by High Dose Statin Therapy
Experimental studies demonstrated that oxidatively modified choline glycerophospholipids (oxPCCD36) are bioactive ligands for the platelet CD36 receptor and promote platelet activation. The interaction of platelet CD36 with endogenous oxidized lipids may play a crucial role in the well established associations between dyslipidemia, oxidant stress and a prothrombotic phenotype. Therefore, plasma levels of the oxPCCD36 oxidized phosphatidycholin-derivates KDdiA-PC (1-(Palmitoyl)-2-(9-keto-10-dodecendioyl)-phophatidylcholin) and KOdiA-PC, (1-(Palmitoyl)-2-(5-keto-6-octendioyl)-phophatidylcholin) were measured by liquid chromatography - tandem mass spectrometry in patients with troponin T positive acute coronary syndromes (ACS; n=13), in patients with documented stable coronary artery disease (CAD; n=28), and in patients with CAD receiving high dose statin therapy (40mg atorvastatin / day) over 4 weeks (n=11).
Results: Plasma levels of KDdiA-PC and KOdiA-PC were significantly elevated in patients with ACS compared to patients with stable CAD (see fig.⇓). Moreover, high dose statin therapy was associated with a significant reduction of both specific oxPCCD36.
Conclusions: These results demonstrate for the first time, that patients with ACS exhibit elevated plasma levels of specific oxidized lipids associated with a prothrombotic phenotype. Moreover, the profound reduction of oxPCCD36 levels by short-term high-dose statin administration may contribute to the well-known anti thrombotic benefits of statin therapy. Future studies will address the prognostic impact of elevated plasma levels of specific oxidized lipids.